AMAG Pharmaceuticals, Inc. to Present at the 28th Annual J.P. Morgan Healthcare Conference


LEXINGTON, Mass.–(BUSINESS WIRE)– AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that Brian J.G. Pereira, MD, President and CEO, will present an overview of the Company and provide an update on the commercial launch of Feraheme(R) (ferumoxytol) Injection at the 28th Annual J.P. Morgan Healthcare Conference on January 11, 2010 at 11:00 a.m. P.T.

A live audio webcast of the presentation and the breakout session will be accessible through the Investors section of the Company’s website at Following the conference, the webcast will be archived on the AMAG Pharmaceuticals, Inc. website until February 11, 2010.

About AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary technology for the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. AMAG received approval from the U.S. Food and Drug Administration to market Feraheme(R) (ferumoxytol) Injection for the treatment of iron deficiency anemia in adult chronic kidney disease patients on June 30, 2009. For additional company and product information, please visit

Feraheme(R) is a registered trademark of AMAG Pharmaceuticals, Inc.

    Source: AMAG Pharmaceuticals, Inc.

Contact: AMAG Pharmaceuticals, Inc. Carol Miceli, 617-498-3361